Drug combination before surgery for advanced mouth or throat cancer
Part of Cancer clinical trials.
This trial tests a combination of two drugs given before surgery for advanced mouth or throat cancer. The drugs may help shrink tumors and improve the chance of successful surgery. It is specifically for patients whose cancer has high levels of PD-L1 and EGFR proteins.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have squamous cell carcinoma of the mouth or throat (not the nasopharynx or skin).
- Your cancer must be at a locally advanced stage (III or IVa) and not spread to distant organs.
- Your tumor must have high levels of two proteins: PD-L1 (a protein used by cancer to hide from the immune system) and EGFR (a protein that helps cancer grow).
- You must not have received any treatment for this cancer before.
- You must be between 18 and 75 years old and in good physical condition (able to take care of yourself).
- You must have adequate kidney, liver, and blood cell counts (your doctor will check with blood tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two or three drugs given before surgery to shrink locally advanced head and neck cancer. The goal is to see if this approach can improve outcomes for patients whose tumors have a specific protein called EGFR.
This trial tests two newer drugs (one targeted therapy, one immunotherapy) given before surgery to shrink mouth cancer and improve outcomes. The goal is to see if combining them is safe and effective for people with stage III-IVA disease.
This trial tests a combination of immunotherapy and targeted therapy to shrink advanced mouth or throat cancer before surgery. It may help make the tumor smaller and easier to remove.
This trial tests two different drug combos—one using an EGFR-targeted therapy alone, the other adding an immunotherapy—before standard chemoradiation for locally advanced head and neck cancer. The goal is to see which approach works better without prior treatment.
This trial tests a new combination of a targeted therapy (EGFR-ADC) and an immunotherapy drug before surgery to shrink and control locally advanced throat cancer. It may help make surgery more effective and reduce the chance of recurrence.
This trial tests a new immunotherapy drug (pucotenlimab) combined with chemotherapy before surgery for head and neck cancer. The goal is to see if this combination shrinks the tumor and improves outcomes for patients with locally advanced disease.
Hear when a new Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.